Biostar Pharma Converts 147.87 Million Unlisted Shares, Expands H-Share Capital to 364.59 Million

Bulletin Express05-06

Beijing Biostar Pharmaceuticals Co., Ltd. (Biostar Pharma) submitted its monthly return to HKEX on 08 April 2026, detailing the completion of full share circulation during March 2026.

The company converted 147.87 million unlisted ordinary shares into H shares on 30 March, increasing registered share capital by 68.24% to RMB 364.59 million. Par value remained unchanged at RMB 1 per share.

Total issued H shares rose from 216.72 million to 364.59 million, while the unlisted share balance fell to zero. No treasury shares were created or cancelled in the process.

Biostar Pharma confirmed that the enlarged H-share class meets the Main Board’s 25% minimum public-float requirement.

The filing shows no outstanding share options, warrants, convertibles, or other equity-linked instruments for the period.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1194399254?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 22:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194399254","market":"us","top_or_hot":-1,"title":"Biostar Pharma Converts 147.87 Million Unlisted Shares, Expands H-Share Capital to 364.59 Million","media":"Bulletin Express","content":"<p>Beijing Biostar Pharmaceuticals Co., Ltd. (Biostar Pharma) submitted its monthly return to HKEX on 08 April 2026, detailing the completion of full share circulation during March 2026.</p>\n<p>The company converted 147.87 million unlisted ordinary shares into H shares on 30 March, increasing registered share capital by 68.24% to RMB 364.59 million. Par value remained unchanged at RMB 1 per share.</p>\n<p>Total issued H shares rose from 216.72 million to 364.59 million, while the unlisted share balance fell to zero. No treasury shares were created or cancelled in the process.</p>\n<p>Biostar Pharma confirmed that the enlarged H-share class meets the Main Board’s 25% minimum public-float requirement.</p>\n<p>The filing shows no outstanding share options, warrants, convertibles, or other equity-linked instruments for the period.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biostar Pharma Converts 147.87 Million Unlisted Shares, Expands H-Share Capital to 364.59 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiostar Pharma Converts 147.87 Million Unlisted Shares, Expands H-Share Capital to 364.59 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-06 22:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Beijing Biostar Pharmaceuticals Co., Ltd. (Biostar Pharma) submitted its monthly return to HKEX on 08 April 2026, detailing the completion of full share circulation during March 2026.</p>\n<p>The company converted 147.87 million unlisted ordinary shares into H shares on 30 March, increasing registered share capital by 68.24% to RMB 364.59 million. Par value remained unchanged at RMB 1 per share.</p>\n<p>Total issued H shares rose from 216.72 million to 364.59 million, while the unlisted share balance fell to zero. No treasury shares were created or cancelled in the process.</p>\n<p>Biostar Pharma confirmed that the enlarged H-share class meets the Main Board’s 25% minimum public-float requirement.</p>\n<p>The filing shows no outstanding share options, warrants, convertibles, or other equity-linked instruments for the period.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02563","symbol_name":"华昊中天医药-B","start_time":0,"source_url":"","article_id":"1194399254","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194399254","pubTimestamp":1778076194,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Beijing Biostar Pharmaceuticals Co., Ltd. (Biostar Pharma) submitted its monthly return to HKEX on 08 April 2026, detailing the completion of full share circulation during March 2026. The company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02563":"华昊中天医药-B"},"translate_title":"映泰制药1.4787亿股非上市股份H股扩股至3.6459亿股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02563":1},"content_text":"Beijing Biostar Pharmaceuticals Co., Ltd. (Biostar Pharma) submitted its monthly return to HKEX on 08 April 2026, detailing the completion of full share circulation during March 2026.\nThe company converted 147.87 million unlisted ordinary shares into H shares on 30 March, increasing registered share capital by 68.24% to RMB 364.59 million. Par value remained unchanged at RMB 1 per share.\nTotal issued H shares rose from 216.72 million to 364.59 million, while the unlisted share balance fell to zero. No treasury shares were created or cancelled in the process.\nBiostar Pharma confirmed that the enlarged H-share class meets the Main Board’s 25% minimum public-float requirement.\nThe filing shows no outstanding share options, warrants, convertibles, or other equity-linked instruments for the period.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1194399254","isCrawlerRequest":true}